Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy

• Published in: Cancer letters 2017-03, Vol.388, p.292-302
• Main Authors: Bharti, Rashmi, Dey, Goutam, Banerjee, Indranil, Dey, Kaushik Kumar, Parida, Sheetal, Kumar, Prashanth B.N, Das, Chandan Kanta, Pal, Ipsita, Mukherjee, Manabendra, Misra, Mridula, Pradhan, Anjan K, Emdad, Luni, Das, Swadesh K, Fisher, Paul B, Mandal, Mahitosh
• Format: Article
• Language: English
• Subjects: Animals; Anthraquinones - pharmacology; Anthraquinones - therapeutic use; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Arthritis; Breast cancer; Breast Neoplasms - drug therapy; Cancer therapies; Diacerein and breast cancer; Female; Growth factors; Hematology, Oncology and Palliative Medicine; Humans; Interleukin-6; Ligands; Lipids; Liposome; Liposomes - metabolism; Mice; Mice, Nude; Nanoparticles; Nanotechnology; Particle size; Receptors, Somatostatin - metabolism; Somatostatin analogue (SST); Spectrum analysis; Studies
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2016.12.021

Abstract Selective targeting to the tumor niche remains a major challenge in successful cancer therapy. Somatostatin receptor 2 (SSTR2) is overexpressed in breast cancer cells thus making this receptor an attractive target for selective guidance of ligand-conjugated drug liposomes to the tumor site. In this study, a synthetic somatostatin analogue (SST) was used as SSTR2 targeting agent and Diacerein was employed as therapeutic molecule. Diacerein loaded liposomes (DNL) were prepared and they were further decorated with the synthetic and stable analogue of somatostatin (SST-DNL). Fabricated liposomes were nano-size in range and biocompatible. SST-DNL displayed significantly better anti-tumor efficacy as compared to free Diacerein (DN) and DNL in breast cancer models. Enhanced apoptosis in breast cancer cells was detected in SST-DNL treated groups as monitored by cell cycle analysis and changes in expression level of apoptotic/anti-apoptotic proteins Bcl-2, Bax, cleaved Caspase 3 and PARP. SST-DNL more effectively inhibited the oncogenic IL-6/IL-6R/STAT3/MAPK/Akt signalling pathways as compared to DN or DNL in cancer cells. In addition, SST-DNL effectively suppressed angiogenesis and cancer cell invasion. In vivo tumor growth in a MDA-MB-231 mouse xenograft model was significantly suppressed following SST-DNL treatment. In xenograft model, immunohistochemistry of Ki-67 and CD-31 indicated that SST-DNL improved the anti-proliferative and anti-angiogenic impacts of Diacerein. In vivo pharmacokinetic studies in rats showed enhanced circulation time in the DNL or SST-DNL treated groups as compared to free DN. Considering all of these findings, we conclude that SST-DNL provides a novel strategy with better efficacy for breast cancer therapy.